Aerie Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Bedminster NJ United States (2005)
Status: Acquired by Novartis (2022)

Organization Overview

First Clinical Trial
2007
NCT00523250
First Marketed Drug
2017
netarsudil
First NDA Approval
2017
netarsudil
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aerie Pharma | Aerie Pharmaceuticals | Aerie Pharmaceuticals Inc. | Aerie Pharmaceuticals, Inc. | Aerie Pharmaceuticals Ireland Ltd. | Aerie Pharmaceuticals Ireland Ltd. (Japan Branch) | AERIE PHARMS INC

Active Ingredients

Marketed Drugs (2)

latanoprost (xalatan) (2019)

netarsudil (2017 NDA)

Drugs in Phase 4 Trials (1)

netarsudil (19 trials)

Drugs in Phase 3 Trials (5)

ar15512 (5 trials)

bimatoprost (lumigan) (1 trial)

latanoprost (xalatan) (6 trials)

ripasudil (Glanatec) (1 trial)

timolol (blocadren) (8 trials)

Drugs in Phase 2 Trials (9)

Key: Aerie Pharmaceuticals (8) Acquired (1)

aflibercept (zaltrap) (2 trials)

AR-13154 (1 trial)

ar-13324 (1 trial)

avx012 (1 trial)

axitinib (inlyta) (1 trial)

dexamethasone (1 trial)

quinine (qualaquin) (1 trial)

travoprost (travatan) (2 trials)

verosudil (8 trials)

Indications

Approved Indications


 

Glaucoma, Open-Angle

Ocular Hypertension

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Edema (Phase 2)

Dry Eye Syndromes (Phase 2)

Edema (Phase 2)

Eye Diseases (Phase 2)

Fuchs' Endothelial Dystrophy (Phase 2)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypertension (Phase 4)

Keratoconjunctivitis Sicca (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Ocular Hypertension (Phase 4)

Retinal Vein Occlusion (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 15